Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure

Sarah M. Bahr, Benjamin J. Weidemann, Ana N. Castro, John W. Walsh, Orlando deLeon, Colin M.L. Burnett, Nicole A. Pearson, Daryl J. Murry, Justin L. Grobe, John R. Kirby

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day) exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.

Original languageEnglish (US)
Pages (from-to)1725-1734
Number of pages10
JournalEBioMedicine
Volume2
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Risperidone
Energy Metabolism
Weight Gain
Transplants
Metabolism
Basal Metabolism
Bacteriophages
Gastrointestinal Microbiome
Inbred C57BL Mouse
Antipsychotic Agents
Bacteria
Modulation
Growth

Keywords

  • Fecal transfer
  • Non-aerobic resting metabolic rate
  • Phage transfer
  • Risperidone induced weight gain

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bahr, S. M., Weidemann, B. J., Castro, A. N., Walsh, J. W., deLeon, O., Burnett, C. M. L., ... Kirby, J. R. (2015). Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine, 2(11), 1725-1734. https://doi.org/10.1016/j.ebiom.2015.10.018

Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. / Bahr, Sarah M.; Weidemann, Benjamin J.; Castro, Ana N.; Walsh, John W.; deLeon, Orlando; Burnett, Colin M.L.; Pearson, Nicole A.; Murry, Daryl J.; Grobe, Justin L.; Kirby, John R.

In: EBioMedicine, Vol. 2, No. 11, 01.11.2015, p. 1725-1734.

Research output: Contribution to journalArticle

Bahr, SM, Weidemann, BJ, Castro, AN, Walsh, JW, deLeon, O, Burnett, CML, Pearson, NA, Murry, DJ, Grobe, JL & Kirby, JR 2015, 'Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure', EBioMedicine, vol. 2, no. 11, pp. 1725-1734. https://doi.org/10.1016/j.ebiom.2015.10.018
Bahr, Sarah M. ; Weidemann, Benjamin J. ; Castro, Ana N. ; Walsh, John W. ; deLeon, Orlando ; Burnett, Colin M.L. ; Pearson, Nicole A. ; Murry, Daryl J. ; Grobe, Justin L. ; Kirby, John R. / Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. In: EBioMedicine. 2015 ; Vol. 2, No. 11. pp. 1725-1734.
@article{b6c6ffe562f0495799f49741a7232097,
title = "Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure",
abstract = "Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day) exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16{\%} reduction in total resting metabolic rate in na{\"i}ve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in na{\"i}ve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.",
keywords = "Fecal transfer, Non-aerobic resting metabolic rate, Phage transfer, Risperidone induced weight gain",
author = "Bahr, {Sarah M.} and Weidemann, {Benjamin J.} and Castro, {Ana N.} and Walsh, {John W.} and Orlando deLeon and Burnett, {Colin M.L.} and Pearson, {Nicole A.} and Murry, {Daryl J.} and Grobe, {Justin L.} and Kirby, {John R.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.ebiom.2015.10.018",
language = "English (US)",
volume = "2",
pages = "1725--1734",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",
number = "11",

}

TY - JOUR

T1 - Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure

AU - Bahr, Sarah M.

AU - Weidemann, Benjamin J.

AU - Castro, Ana N.

AU - Walsh, John W.

AU - deLeon, Orlando

AU - Burnett, Colin M.L.

AU - Pearson, Nicole A.

AU - Murry, Daryl J.

AU - Grobe, Justin L.

AU - Kirby, John R.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day) exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.

AB - Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day) exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.

KW - Fecal transfer

KW - Non-aerobic resting metabolic rate

KW - Phage transfer

KW - Risperidone induced weight gain

UR - http://www.scopus.com/inward/record.url?scp=84958879311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958879311&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2015.10.018

DO - 10.1016/j.ebiom.2015.10.018

M3 - Article

C2 - 26870798

AN - SCOPUS:84958879311

VL - 2

SP - 1725

EP - 1734

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

IS - 11

ER -